Market research
NOVN Novan Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- 0.0%
- Beta
- -0.04
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- US66988N2053
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- 0.0%
- Beta
- -0.04
About
About Novan Inc
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NOVN discussion.
5 years, 4 months ago
Novan, Inc is currently in a long term downtrend where the price is trading 15.0% below its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.7.
Novan, Inc's total revenue sank by 22.5% to $1M since the same quarter in the previous year.
Its net income has dropped by 335.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.6% to $-9M since the same quarter in the previous year.
Based on the above factors, Novan, Inc gets an overall score of 1/5.